Expression, Prognostic Value and Correlation with HPV Status of Hypoxia-Induced Markers in Sinonasal Squamous Cell Carcinoma.
hypoxia
hypoxic markers
immunohistochemistry
overall survival
squamous cell carcinoma
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
29 Apr 2023
29 Apr 2023
Historique:
received:
29
03
2023
revised:
26
04
2023
accepted:
28
04
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
(1) Background: In head and neck squamous cell carcinoma, tumor hypoxia has been associated with radio/chemoresistance and poor prognosis, whereas human papillomavirus (HPV)-positive status has a positive impact on treatment response and survival outcomes. The aim of this study was to evaluate the expression and the potential prognostic value of hypoxia-induced endogenous markers in patients treated for squamous cell carcinoma of the nasal cavity and paranasal sinuses (SNSCC), and their correlation with HPV status. (2) Methods: In this monocentric study, patients treated in a curative intent for a SNSCC were screened retrospectively. Protein expression of CA-IX, GLUT-1, VEGF, VEGF-R1, and HIF-1α was determined by immunohistochemical staining, scored, and then correlated with overall survival (OS) and locoregional recurrence free survival (LRRFS). HPV status was assessed and correlated with hypoxic markers. (3) Results: 40 patients were included. A strong expression of CA-IX, GLUT-1, VEGF, and VEGF-R1 was detected in 30%, 32.5%, 50%, and 37.5% of cases, respectively. HIF-1α was detected in 27.5% of cases. High CA-IX expression was associated in univariate analysis with poor OS (
Identifiants
pubmed: 37240937
pii: jpm13050767
doi: 10.3390/jpm13050767
pmc: PMC10222519
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oral Oncol. 2002 Apr;38(3):251-7
pubmed: 11978547
J Med Imaging Radiat Oncol. 2014 Feb;58(1):89-97
pubmed: 24529061
Cancers (Basel). 2022 Apr 08;14(8):
pubmed: 35454782
Laryngoscope. 2002 Feb;112(2):393-6
pubmed: 11889403
Pathology. 2019 Jun;51(4):421-425
pubmed: 31005250
Head Neck. 2012 Jun;34(6):877-85
pubmed: 22127982
Radiother Oncol. 2000 Oct;57(1):39-43
pubmed: 11033187
Br J Cancer. 2015 Jan 20;112(2):238-50
pubmed: 25514380
JAMA Netw Open. 2023 Feb 1;6(2):e2255971
pubmed: 36787144
Int J Mol Sci. 2021 Dec 14;22(24):
pubmed: 34948200
Head Neck. 2013 Oct;35(10):1507-14
pubmed: 22987573
Head Neck. 2005 Jul;27(7):622-38
pubmed: 15952198
Oncologist. 2004;9 Suppl 5:31-40
pubmed: 15591420
Cancer Treat Rev. 2015 Dec;41(10):844-52
pubmed: 26476574
Int Forum Allergy Rhinol. 2015 Jan;5(1):85-91
pubmed: 25278180
Eur Arch Otorhinolaryngol. 2011 May;268(5):661-70
pubmed: 21246209
Acta Oncol. 2018 Sep;57(9):1152-1158
pubmed: 29578367
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359578
Radiother Oncol. 2012 Jan;102(1):122-9
pubmed: 21996521
Oncotarget. 2019 Apr 30;10(32):3066-3083
pubmed: 31105886
Laryngoscope. 2014 Jan;124(1):76-83
pubmed: 23775607
PLoS One. 2013 Sep 13;8(9):e75094
pubmed: 24058651
Hum Pathol. 2018 Aug;78:63-71
pubmed: 29684499
Annu Rev Pathol. 2014;9:47-71
pubmed: 23937437
Br J Radiol. 2019 Jan;92(1093):20180047
pubmed: 29493265
BMC Cancer. 2005 Apr 25;5:42
pubmed: 15847702
Cancers (Basel). 2020 Dec 25;13(1):
pubmed: 33561073
Head Neck. 2007 Jun;29(6):591-604
pubmed: 17252597
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1192-202
pubmed: 12128120
Oncotarget. 2016 Aug 2;7(31):50781-50804
pubmed: 27434126
Ann Diagn Pathol. 2020 Dec;49:151643
pubmed: 33126151
Recent Results Cancer Res. 2016;198:123-42
pubmed: 27318684
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):17-25
pubmed: 10924967
Curr Oncol Rep. 2022 Jan;24(1):55-67
pubmed: 35059992
Am J Nucl Med Mol Imaging. 2014 Jun 07;4(4):365-84
pubmed: 24982822